Esther Martinborough
Director/Board Member at CODEXIS, INC.
Net worth: 202 186 $ as of 2024-03-30
Profile
Esther Martinborough is an Independent Director at Codexis, Inc. since 2021.
She is also the Chief Scientific Officer at Escient Pharmaceuticals, Inc. since 2018.
Prior to her current positions, she worked as the Executive Director-Research at Receptos LLC from 2008 to 2018.
Dr. Martinborough holds a doctorate degree from the Swiss Federal Institute of Technology and a graduate degree from the University of California.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
CODEXIS, INC.
0.08% | 2024-04-17 | 57,933 ( 0.08% ) | 202 186 $ | 2024-03-30 |
Esther Martinborough active positions
| Companies | Position | Start |
|---|---|---|
| CODEXIS, INC. | Director/Board Member | 2021-02-01 |
Escient Pharmaceuticals, Inc.
 Escient Pharmaceuticals, Inc. BiotechnologyHealth Technology Escient Pharmaceuticals, Inc. operates as a bio-technology company. It develops in-class G Protein-Coupled Receptor targeted drugs to address serious, unserved medical needs. The company was founded by Alain D. Baron, Marcus F. Boehm and Xinzhong Dong and is headquartered in San Diego, CA. | Chief Tech/Sci/R&D Officer | 2023-03-31 |
Former positions of Esther Martinborough
| Companies | Position | End |
|---|---|---|
| RECEPTOS INC | Director/Board Member | 2014-12-31 |
Training of Esther Martinborough
| Swiss Federal Institute of Technology | Doctorate Degree |
| University of California | Graduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| CODEXIS, INC. | Process Industries |
| Private companies | 2 |
|---|---|
Receptos LLC
 Receptos LLC Pharmaceuticals: MajorHealth Technology Receptos LLC engages in the provision of developing and commercializing of therapeutic candidates for the treatment of immune and inflammatory diseases. It offers Ozanimod for relapsing multiple sclerosis, Ozanimod for inflammatory bowel disease and RPC4046 for eosinophilic esophagitis. The company was founded by Marcus F. Boehm, Robert J. Peach, William H. Rastetter, Hugh Rosen and Raymond C. Stevens on September 26, 2008 and is headquartered in San Diego, CA. | Health Technology |
Escient Pharmaceuticals, Inc.
Escient Pharmaceuticals, Inc. BiotechnologyHealth Technology Escient Pharmaceuticals, Inc. operates as a bio-technology company. It develops in-class G Protein-Coupled Receptor targeted drugs to address serious, unserved medical needs. The company was founded by Alain D. Baron, Marcus F. Boehm and Xinzhong Dong and is headquartered in San Diego, CA. | Health Technology |
- Stock Market
- Insiders
- Esther Martinborough
